CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病预防

Abstract

Recommended Article

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials The Science Underlying COVID-19: Implications for the Cardiovascular System Endocardium Minimally Contributes to Coronary Endothelium in the Embryonic Ventricular Free Walls CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design

Editorial2019 Aug 7;40(30):2492-2494.

JOURNAL:Eur Heart J. Article Link

When, where, and how to target vascular inflammation in the post-CANTOS era?

Maffia P, Guzik TJ. Keywords: atherosclerosis; target vascular inflammation; CANTOS trial; secondary prevention; history of myocardidal infarction; IL-1 pathway

LINK


This editorial refers to ‘Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis’, by A. Vrommanetal., doi:10.1093/eurheartj/ehz008